Hematologic Risk Factors for the Development of Retinopathy of Prematurity-A Retrospective Study

• Published in: Children (Basel) Vol. 10; no. 3; p. 567
• Main Authors: Zonda, Gabriela Ildiko, Mogos, Raluca, Melinte-Popescu, Alina-Sînziana, Adam, Ana-Maria, Harabor, Valeriu, Nemescu, Dragos, Socolov, Demetra, Harabor, Anamaria, Melinte-Popescu, Marian, Hincu, Maura Adelina, Vasilache, Ingrid-Andrada, Carauleanu, Alexandru, Adam, Gigi, Paduraru, Luminita
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 01-03-2023; MDPI
• Subjects: Biomarkers; Birth weight; Blindness; Blood platelets; Gestational age; Health aspects; hematological parameters; Hematology; Hospitals; Infants (Newborn); Lung diseases; Medical research; Medicine, Experimental; Newborn babies; Pathogenesis; Pediatric research; Physiological aspects; platelet mass index; Regression analysis; Retinal diseases; retinopathy of prematurity; Retrolental fibroplasia; risk factor identification; Risk factors; Sensitivity analysis; Vascular endothelial growth factor; Romania; Taiwan; platelet mass index; risk factor identification; retinopathy of prematurity; hematological parameters
• ISSN: 2227-9067; 2227-9067
• DOI: 10.3390/children10030567

(1) Background: Retinopathy of prematurity (ROP) can cause severe visual impairment or even blindness. We aimed to assess the hematological risk factors that are associated with different stages of ROP in a cohort of preterm newborns, and to compare the clinical characteristics and therapeutic interventions between groups. (2) Methods: This retrospective study included 149 preterm newborns from a tertiary maternity hospital in Romania between January 2018 and December 2018, who were segregated into: Group 1 (with ROP,
= 59 patients), and Group 2 (without ROP,
= 90 patients). The patients that were affected by ROP were subsequently divided into the following subgroups: Subgroup 1 (Stage 1,
= 21), Subgroup 2 (Stage 2,
= 35), and Subgroup 3 (Stage 3,
= 25). The associations were analyzed using multivariate logistic regression and sensitivity analysis. (3) Results: Platelet mass indexes (PMI) that were determined in the first, seventh, and tenth days of life were significantly associated with Stage 1 ROP. PMI determined in the first day of life was also significantly associated with Stage 2 ROP. The sensitivity and specificity of these parameters were modest, ranging from 44 to 57%, and 59 to 63%. (4) Conclusions: PMI has a modest ability to predict the development of ROP.